Prosensa picked the right day to price its IPO. The Dutch biotech rang up the offering at $13 a share, at the top of the range, raising $78 million after bumping the number of shares on offer to 6 million. The stock will trade on Nasdaq as "RNA."
Resverlogix fell hard this afternoon on news that the company fell short in a midstage study of its lead HDL cholesterol-boosting drug. The Calgary-based biotech company said the Phase IIb study of RVX-208 failed to meet the goal of change in percent of atheroma volume in patients with a high risk of developing cardiovascular disease.
The Cambridge, MA, center is one of four planned by J&J.
Eli Lilly is pitching in $10 million to fund the Indiana Biosciences Research Institute, a public-private life sciences organization launched by local luminaries Cook Medical, Biomet and Roche Diagnostics.
A stealth biotech spun out of Stanford University burst into public view today, drawing headlines around the world for its new therapeutic approach to Type 1 diabetes that aims to completely change the standard of care in the field.
Diabetes treatments either fail to stop the decline of insulin-releasing cells, or put patients at risk by shutting off other bits of the immune system too. New data suggest that DNA vaccines could help preserve the remaining pancreatic insulin-producing beta cells without causing serious side effects.
California startup Middle Peak Medical locked down an $8.5 million Series A to support the development of its device to treat mitral regurgitation, targeting a market haunted by Abbott Laboratories.
Esperion Therapeutics got a warm reception after an upsized IPO that hauled in $70 million. The Plymouth, MI-based biotech company increased the offering size from 4.5 million to 5 million shares at $14 per share, hitting the midpoint of its proposed range of $13 to $15 per share.
Cruise ships, take heart. Takeda Pharmaceuticals is leading the efforts to develop a vaccine against norovirus, the vomiting bug that has crippled pleasure ships and afflicted schools.
his experimental vaccine combines components of two types of norovirus, which Takeda believes should provide an effective guard against all the viral strains in circulation.